Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tianyin Pharma Hits Targets for Fiscal Q2

publication date: Feb 9, 2010
Tianyin Pharmaceutical Co. reported its revenues rose 48% during the company’s fiscal Q2 (December 31, 2009) to $14.9 million. Net income was up a smaller 25% at $2.6 million. When combined with a much larger number of shares outstanding, the company’s earnings per share actually slipped to 11 cps from 13 cps one year ago. Tianyin has traditionally been a TCM company, but it is branching into generic western drugs, with a special emphasis on macrolide antibiotics. More details...

Stock Symbol: (NYSE Alternext: TPI)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here